You have no items in your shopping cart.
Comparison of Anti-Human CD38 Clones HB7 vs. HIT2
CD38 (NAD+ glycohydrolase) is a type II transmembrane protein that plays multiple roles in the immune system. It can activate, promote growth, and guide the development of mature lymphocytes, as well as trigger the programmed death (apoptosis) of myeloid and lymphoid precursor cells.
Additionally, CD38’s enzymatic activity, located on its extracellular part, enables it to convert NAD+ into ADP-ribose, generate cyclic ADP-ribose (cADPR), and break down cADPR.These processes influence the levels of metabolites involved in calcium signaling. The ADP-ribose produced by CD38 acts as a key signaling molecule for the movement of neutrophils and dendritic cells. CD38 is also a marker for certain B cell populations, leukemia, and a significant target for immunotherapy in treating multiple myeloma.
Spotlight: Comparing CD38 Antibody Clones HB7 vs. HIT2
This issue focuses on two FITC-conjugated anti-CD38 antibodies derived from different clones, HB7 (orb2281308) and HIT2 (orb43853). These antibodies were analyzed to compare their reactivity with various populations of human peripheral blood leukocytes and B cells.
Key Findings:
1. Both HB7 and HIT2 clones demonstrated comparable reactivity patterns.
2. Their specificity for CD38 was confirmed across all tested populations.
Reactivity in Peripheral Blood Leukocytes
Figure 1 shows the reactivity patterns of FITC-labeled anti-CD38 clones HB7 and HIT2 with different populations of human peripheral blood leukocytes. These patterns confirm the reliable performance of both clones across diverse cell types.
Figure 2: Reactivity of anti-CD38 clones HB7 and HIT2, labeled with FITC, is shown on B cells and compared based on CD27 expression.
Figure 3: The reactivity patterns of FITC-labeled anti-CD38 clones HB7 and HIT2 are shown on B cells, evaluated relative to CD138 expression.
Conclusion
Both HB7 and HIT2 anti-CD38 clones exhibit strong, specific reactivity, making them valuable tools for research and clinical applications. Their performance in identifying leukocyte populations and B cell subsets supports their continued use in studies of immune function and therapeutic targeting.
Below, you can explore both unconjugated and FITC-conjugated versions of these antibodies:
If you have any questions, don’t hesitate to reach out to our support team - [email protected]
January 2025
